Specialties
Sean Ronnekleiv-Kelly, MD, FACS
Associate Professor
- Endowed Professor, Ronald E. and Patricia A. Kissinger Surgical Oncology Research Professorship
- Division of Surgical Oncology
ronnekleiv-kelly@surgery.wisc.edu
- Administrative Assistant: (608) 262-2025
600 Highland Avenue
Clinical Science Center
Madison WI 53792-7375
Education
- MD, University of Colorado School of Medicine
- General Surgery Residency, University of Wisconsin School of Medicine and Public Health
- Complex General Surgical Oncology Fellowship, Johns Hopkins Hospital
Clinical Specialties
Certified by the American Board of Surgery in General Surgery and specializes in malignant disease of the pancreas, liver, gallbladder and biliary tree, stomach and small intestine, neuroendocrine tumors and retroperitoneal sarcoma.
Research Interests
Principal research interest is pancreatic cancer. My lab focuses on formation and progression of pancreatic cancer as well as understanding communication within the tumor microenvironment.
Dr. Sean Ronnekleiv-Kelly was awarded a two-year, $276,000 grant from the Fibrolamellar Cancer Foundation. Read more here.
Dr. Ronnekleiv-Kelly received a two-year, $528,000 grant from the Fibrolamellar Cancer Foundation. Read more here.
Recent Publications
The DNAJB1-PRKACA Oncogenic Fusion Drives Stepwise Biliary and Pancreatic Carcinogenesis from Intraductal Precursor Lesions.
Carney PR, Nukaya M, Carter JA, Veltri AJ, Matkowskyj KA, Stram A, Rubinstein CD, Veith AC, Pillarisetty VG, Bradfield CA, Ronnekleiv-Kelly SM
bioRxiv 2026 May 27;
[PubMed ID: 42244708]Single-cell Transcriptomic Variance Analysis Reveals Intercellular Circadian Desynchrony in the Alzheimer's Affected Human Brain.
Hollis HC, Veltri A, Korac K, Menon V, Bennett DA, Ronnekleiv-Kelly SM, Kim J, Anafi RC
bioRxiv 2026 Mar 25;
[PubMed ID: 41929229]Correction: DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK, Tsai PY, Farghli AR, Shumway A, Kanke M, Gordan JD, Gujral TS, Vakili K, Nukaya M, Noetzli L, Ronnekleiv-Kelly S, Broom W, Barrow J, Sethupathy P
PLoS Genet 2026 Feb; 22(2): e1012054
[PubMed ID: 41746900]CDK7 is a novel therapeutic target in fibrolamellar carcinoma.
Nukaya M, Carney PR, Cafferty C, Zahed K, Yun I, Al-Adra DP, Kazim NA, Farghli AR, Chan M, Stram A, Kratz JD, Berres ME, Yen A, Gujral TS, Sethupathy P, Bradfield CA, Ronnekleiv-Kelly SM
iScience 2025 Dec 19; 28(12): 113925
[PubMed ID: 41321622]Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Benson AB, D'Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M, Baker M, Binder D, Brown DB, Burgoyne A, Castellanos J, Cloyd J, Cullinan D, Franses J, Glazer ES, Harris W, Iyer R, Jennings L, Kelley RK, Khan S, Levine M, Melstrom L, Palta M, Raman S, Ronnekleiv-Kelly S, Sahai V, Stein S, Stephans K, Thanikachalam K, Turk A, Vauthey JN, Venook AP, Yano M, Yopp A, Zhao K, Schonfeld R, Hochstetler C
J Natl Compr Canc Netw 2025 Sep; 23(9): 403-418
[PubMed ID: 40930144]